Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Amgen and Ideaya ax cancer combination trial
Amgen and Ideaya mutually agreed to wind the current study down and drop plans to start dose expansion.
Nick Paul Taylor
Feb 13, 2025 7:34am
Valerio ends all clinical activity, shuts down US site
Feb 4, 2025 12:09pm
Turnstone ends final TIL program over costs, plots more layoffs
Feb 4, 2025 10:30am
Pfizer axes B7-H4 ADC, triggering $1B impairment charge
Feb 4, 2025 8:46am
Roche drops HER2 bispecific, Xencor-partnered cytokine
Jan 30, 2025 4:56am
Avacta hits 10% response rate, adds peptide-drug conjugate arms
Jan 16, 2025 8:51am
